Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real‐world evidence

Documenti analoghi

• Translating 6‐year trial safety data of upadacitinib in atopic dermatitis into clinical practice
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Addressing potential bias when assessing safety of biologics and JAK inhibitors in atopic dermatitis
  di: Lian F. van der Gang, et al.
  Pubblicazione: (2026)
• Efficacy of abrocitinib and dupilumab in itch‐dominant atopic dermatitis: An analysis of 2 trials
  di: Jonathan I. Silverberg, et al.
  Pubblicazione: (2026)
• The real‐world, long‐term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study
  di: Khalaf Kridin, et al.
  Pubblicazione: (2025)
• Five‐year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real‐world study
  di: Luigi Gargiulo, et al.
  Pubblicazione: (2025)